SecBot SecBot
8-K ·Filed May 7, 2026

HRMY

Harmony Biosciences Holdings, Inc.
MIXED
Impact 5/10
Horizondays Processed6mo ago SEC0001104659-26-056786
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The Q1 miss is largely due to one-time IPR&D charges, but the underlying business continues to grow. The maintained full-year guidance and strong cash position support the long-term story. Traders should watch for post-earnings volatility and the upcoming pitolisant GR NDA submission in Q2 2026 as a near-term catalyst.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.42
T+0 close · May 7, 2026 · via day close
Latest settled
+13.30%
T+60 · $35.60
Vs SPY
+9.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $31.42entry
  2. T+1 · 6mo ago −1.37%α −2.20% · $30.99
  3. T+5 · 6mo ago −1.88%α −3.38% · $30.83
  4. T+20 · 6mo ago +2.16%α −0.97% · $32.10
  5. T+60 · 4mo ago +13.30%α +9.47% · $35.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Harmony Biosciences reported Q1 2026 revenue of $215.4M (+17% YoY), slightly below consensus of $220.8M. GAAP diluted EPS of $0.55 missed consensus of $0.93 by 41%, driven by $32M in upfront license payments. The company reaffirmed FY2026 revenue guidance of $1.0B-$1.04B, citing continued WAKIX growth and pipeline progress.

Key Financial Metrics

EPS
$0.55
est $0.93 · -40.9%
Revenue
$215.4M
est $220.8M · -2.5% · +17.0% YoY
Rating
strong miss
Guidance
$1.0B-$1.04B
maintained
Gross Margin
79.3%

Key Facts

  • Q1 2026 net product revenue $215.4M, +17% YoY ($184.7M)
  • GAAP net income $32.5M ($0.55 diluted) vs $45.6M ($0.78) in Q1 2025
  • EPS missed consensus ($0.93) by 41% due to $32M in upfront license payments ($0.45 after-tax impact)
  • Reiterated FY2026 revenue guidance of $1.0B-$1.04B
  • Cash, equivalents and investments of $870.5M at quarter end
  • R&D expenses surged 101% to $69.4M, driven by license agreement costs
  • Cost of product sold as % of revenue rose to 20.7% from 17.3% due to new royalties
  • Completed settlements with 6 of 7 ANDA filers; filed patent suit against AET Pharma/Sandoz

Financial Impact

Q1 2026 revenue $215.4M (+17% YoY); GAAP EPS $0.55 vs $0.93 consensus; net income $32.5M vs $45.6M YoY

revenueepsoperating incomecash

Risk Factors

  • EPS miss could weigh on near-term sentiment despite explanation
  • Rising cost of product sold (royalties) may pressure margins
  • Execution risk on pipeline (pitolisant GR NDA, BP-205 data)
  • Potential generic competition post-2030

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
65% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-056786
Document: hrmy-20260507x8k.htm0001104659-26-056786
Document: hrmy-20260507xex99d2.htm0001104659-26-056786
Document: 0001104659-26-056786-index-headers.html0001104659-26-056786
Document: 0001104659-26-056786-index.html0001104659-26-056786
Document: 0001104659-26-056786.txt0001104659-26-056786
8-K Data (Synthetic)0001104659-26-056786

Track record

20 reports on HRMY

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
  2. Nov 4, 202612d ago 8-K Bearish 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $34.42 Now $32.96 +4.23% settles Dec 3
  4. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
  5. Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
  6. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
  7. Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
  8. Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
  9. Aug 4, 202614w ago 8-K Bullish 7/10 No price data
  10. Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
Showing 10 of 20

US Market Status

Market Closed · Opens in 8h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026